Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely
Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...
EurekAlert!3d
New Alzheimer’s studies reveal disease biology, risk for progression, and the potential for a novel blood test
Two new papers by a team of researchers at Boston University, the Indiana University School of Medicine and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the German Center for ...
How Novartis plans to thrive without competing directly with Eli Lilly in weight loss drug market
Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 ...
Kyverna Therapeutics Announces Leadership Update
Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell ...
Medpage Today on MSN5d
Another Possible Treatment Option for Intermediate-Stage Liver Cancer
Progression-free survival (PFS) in intermediate-stage hepatocellular carcinoma (HCC) improved by almost 5 months when a ...